Evaluation of a Hemostatic and Sealing Agent to Prevent Surgical Complications After Axillary Lymphadenectomy
Phase 4
Completed
- Conditions
- Seroma
- Registration Number
- NCT00852826
- Lead Sponsor
- Hospital Universitario Virgen de la Arrixaca
- Brief Summary
This study was intended to assess the value of a hemostatic and sealing agent, a collagen sponge coated with human coagulation factors (fibrinogen and thrombin) (TachoSil®), for decreasing occurrence of seroma after axillary lymphadenectomy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Patients with axillary lymphadenectomies performed for oncological conditions.
Exclusion Criteria
- Patients that did not want to participate in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of TachoSil® collagen sponges reduce seroma formation post-axillary lymphadenectomy?
How does TachoSil® compare to fibrin sealants in preventing seroma after breast cancer lymph node surgery?
Are there specific biomarkers that predict TachoSil® efficacy in axillary lymphadenectomy patients?
What adverse events are associated with fibrinogen-thrombin coated hemostatic agents in surgical settings?
What combination therapies with hemostatic agents show promise in post-lymphadenectomy complication prevention?
Trial Locations
- Locations (1)
Hospital Universitario "Virgen de la Arrixaca"
🇪🇸Murcia, Spain
Hospital Universitario "Virgen de la Arrixaca"🇪🇸Murcia, Spain